- Home
- GSIW vs VYNE Comparison
GSIW vs VYNE Comparison
Compare GSIW & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSIW
- VYNE
- Stock Information
- Founded
- GSIW 2016
- VYNE 2003
- Country
- GSIW Hong Kong
- VYNE United States
- Employees
- GSIW N/A
- VYNE N/A
- Industry
- GSIW
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- GSIW
- VYNE Health Care
- Exchange
- GSIW Nasdaq
- VYNE Nasdaq
- Market Cap
- GSIW 8.1M
- VYNE 9.6M
- IPO Year
- GSIW 2023
- VYNE 2018
- Fundamental
- Price
- GSIW $0.15
- VYNE $0.37
- Analyst Decision
- GSIW
- VYNE Buy
- Analyst Count
- GSIW 0
- VYNE 2
- Target Price
- GSIW N/A
- VYNE $8.00
- AVG Volume (30 Days)
- GSIW 5.9M
- VYNE 3.1M
- Earning Date
- GSIW 01-01-0001
- VYNE 11-10-2025
- Dividend Yield
- GSIW N/A
- VYNE N/A
- EPS Growth
- GSIW N/A
- VYNE N/A
- EPS
- GSIW N/A
- VYNE N/A
- Revenue
- GSIW $5,368,221.00
- VYNE $476,000.00
- Revenue This Year
- GSIW N/A
- VYNE N/A
- Revenue Next Year
- GSIW N/A
- VYNE N/A
- P/E Ratio
- GSIW N/A
- VYNE N/A
- Revenue Growth
- GSIW 283.23
- VYNE N/A
- 52 Week Low
- GSIW $0.09
- VYNE $0.28
- 52 Week High
- GSIW $1.79
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- GSIW 47.93
- VYNE 49.90
- Support Level
- GSIW $0.15
- VYNE $0.34
- Resistance Level
- GSIW $0.16
- VYNE $0.39
- Average True Range (ATR)
- GSIW 0.02
- VYNE 0.04
- MACD
- GSIW 0.00
- VYNE 0.00
- Stochastic Oscillator
- GSIW 17.99
- VYNE 30.38
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.